USO 15013

(GO29436) a phase iii, open-label, randomized study of mpdl3280a (anti−pd-l1 antibody) in combination with carboplatin + paclitaxel with or without bevacizumab compared with carboplatin + paclitaxel + bevacizumab in chemotherapy-naïve patients with stage iv non-squamous non−small cell lung cancer

Disease Types

Lung Cancer

Available at

BethesdaClintonColumbiaRockvilleSilver SpringWheaton


Cheryl A. Young, RN, BSN
(410) 964-2212 ext 1137